Taipei, June 13, 2025 —ImmunAdd Inc., a Taiwan-based biotech company, announced its participation in the 2025 BIO International Convention, taking place June 16–19 at the Boston Convention and Exhibition Center. The company will present its latest advancements in synthetic vaccine adjuvants and immune modulation technologies to the global biotech community. At this year’s convention, ImmunAdd […]

TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, attended to WVC Washington during 4/2~4/4. ImmunAdd is a group of scientists with extensive knowledge of medical chemistry, drug formulation, drug regulations, biological animal evaluation, and clinical trials, and is working on developing drugs for infectious disease, […]

TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, attends BIO International Convention during 6/3~6/6 and will be in Taiwan Pavilon (Booth: 1917). ImmunAdd developed a synthetic saponin IA-05 which can be synthesized in large scale and manufactured in GMP facility. IA-05 is formulated in aqueous […]

ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the Vaccines Summit 2022 in Washington DC on October 11-13. Founder of ImmunAdd, Pi-Hui Liang, said “My team and I were delighted to attend the Vaccines Summit, an internationally renowned academic conference, where we presented a poster […]

ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the BIO International Convention conference in San Diego, California, on June 13-16. Founder of ImmunAdd, Pi-Hui Liang, said, “My team and I are delighted to attend the BIO conference in San Diego, where we will show our […]